Tags

Type your tag names separated by a space and hit enter

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Maturitas. 2005 Sep 16; 52(1):1-10.M

Abstract

Controversies about the safety of different postmenopausal hormone therapies (HTs) started 30 years ago and reached a peak in 2003 after the publication of the results from the Women Health Initiative (WHI) trial and the Million Women Study (MWS) [Writing group for the women's health initiative investigations. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33; Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-27]. The single HT formulation used in the WHI trial for non hysterectomized women-an association of oral conjugated equine estrogens (CEE-0.625 mg/day) and a synthetic progestin, medroxyprogesterone acetate (MPA-2.5 mg/day)-increases the risks of venous thromboembolism, cardiovascular disease, stroke and breast cancer. The MWS, an observational study, showed an increased breast cancer risk in users of estrogens combined with either medroxyprogesterone acetate (MPA), norethisterone, or norgestrel. It is unclear and questionable to what extent these results might be extrapolated to other HRT regimens, that differ in their doses, compositions and administration routes, and that were not assessed in the WHI trial and the MWS. Significant results were achieved with the publication of the WHI estrogen-only arm study [Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712] in which hormone therapy was reserved to women who had carried out hysterectomy. What emerged from this study will allow us to have some important argument to develop.

Authors+Show Affiliations

University of Modena and Reggio Emilia, Institute of Cardiology, Modena, Italy. modena.mariagrazia@unimore.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15963666

Citation

Modena, Maria Grazia, et al. "New Evidence Regarding Hormone Replacement Therapies Is Urgently Required Transdermal Postmenopausal Hormone Therapy Differs From Oral Hormone Therapy in Risks and Benefits." Maturitas, vol. 52, no. 1, 2005, pp. 1-10.
Modena MG, Sismondi P, Mueck AO, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
Modena, M. G., Sismondi, P., Mueck, A. O., Kuttenn, F., Lignières, B. d., Verhaeghe, J., Foidart, J. M., Caufriez, A., & Genazzani, A. R. (2005). New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas, 52(1), 1-10.
Modena MG, et al. New Evidence Regarding Hormone Replacement Therapies Is Urgently Required Transdermal Postmenopausal Hormone Therapy Differs From Oral Hormone Therapy in Risks and Benefits. Maturitas. 2005 Sep 16;52(1):1-10. PubMed PMID: 15963666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. AU - Modena,Maria Grazia, AU - Sismondi,Piero, AU - Mueck,Alfred O, AU - Kuttenn,Frédérique, AU - Lignières,Bruno de, AU - Verhaeghe,Johan, AU - Foidart,Jean Michel, AU - Caufriez,Anne, AU - Genazzani,Andrea Riccardo, AU - ,, PY - 2004/07/29/received PY - 2005/04/21/revised PY - 2005/05/12/accepted PY - 2005/6/21/pubmed PY - 2005/12/13/medline PY - 2005/6/21/entrez SP - 1 EP - 10 JF - Maturitas JO - Maturitas VL - 52 IS - 1 N2 - Controversies about the safety of different postmenopausal hormone therapies (HTs) started 30 years ago and reached a peak in 2003 after the publication of the results from the Women Health Initiative (WHI) trial and the Million Women Study (MWS) [Writing group for the women's health initiative investigations. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33; Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-27]. The single HT formulation used in the WHI trial for non hysterectomized women-an association of oral conjugated equine estrogens (CEE-0.625 mg/day) and a synthetic progestin, medroxyprogesterone acetate (MPA-2.5 mg/day)-increases the risks of venous thromboembolism, cardiovascular disease, stroke and breast cancer. The MWS, an observational study, showed an increased breast cancer risk in users of estrogens combined with either medroxyprogesterone acetate (MPA), norethisterone, or norgestrel. It is unclear and questionable to what extent these results might be extrapolated to other HRT regimens, that differ in their doses, compositions and administration routes, and that were not assessed in the WHI trial and the MWS. Significant results were achieved with the publication of the WHI estrogen-only arm study [Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712] in which hormone therapy was reserved to women who had carried out hysterectomy. What emerged from this study will allow us to have some important argument to develop. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/15963666/New_evidence_regarding_hormone_replacement_therapies_is_urgently_required_transdermal_postmenopausal_hormone_therapy_differs_from_oral_hormone_therapy_in_risks_and_benefits_ DB - PRIME DP - Unbound Medicine ER -